Bart's Mesothelioma Research

Aiming for Excellence in Mesothelioma Treatment and Research

Clinical Trials and Chemotherapy

Irinotecan, mitomycin and cisplatin (‘IPM’) for the first-line or second-line treatment of pleural mesothelioma. This intensive chemotherapy treatment causes cancer shrinkage in around 30-40% of patients with mesothelioma. Side effects can include lack of energy, nausea and hair loss. The treatment is given every two weeks as an outpatient. Not all patients are suitable for IPM treatment but many patients have benefited from the tumour shrinkage achievable.

Weekly vinorelbine chemotherapy for the first-line or second-line treatment of pleural mesothelioma. This less-toxic chemotherapy treatment causes cancer shrinkage in around 20% of patients with mesothelioma. Side effects can include lack of energy, nausea and constipation. The treatment is given weekly as an outpatient. Patients sometimes respond to vinorelbine chemotherapy after previous different chemotherapy treatment.

Weekly vinorelbine chemotherapy for the first-line treatment of peritoneal mesothelioma. Patients with peritoneal mesothelioma have a similar chance of benefit as patients with pleural mesothelioma. We offer weekly vinorelbine chemotherapy as our treatment for patients with peritoneal mesothelioma.

We also offer all other conventional mesothelioma treatments. New clinical trials are in development all the time so please watch the site for updates.